Latest Breaking News On - From concept - Page 14 : comparemela.com

GAITHERSBURG, Md. and SUZHOU, China, June 22, 2022 /PRNewswire/ Sirnaomics Ltd.(the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that the Company's Chief Technology Officer, Dmitry Samarsky, PhD, will present the latest developments and expanded applications of its Dual-Targeted RNAi therapeutics based on its proprietary GalAhead technology and product pipeline, at the 4th Annual RNA Therapeutic: From Concept to Clinic Symposium. The Symposium will take place virtually on June 22-24, 2022. Sirnaomics' proprietary GalNAc-RNAi therapeutic platform, GalAhead, relies on unique RNA structures that allow the knockdown of single or multiple distinct mRNA targets, specifically two key technological components: mxRNA (miniaturized RNAi triggers) and muRNA (multi-unit RNAi triggers). mxRNAs are comprised of single ~30 nt long oligonucleotides to downregulate individu

United statesNigel yipDmitry samarskyBunny leeAlexis feinbergPatrick luSirnaomics ltdPrnewswire sirnaomics ltdCompany or sirnaomicsChief technology officerFrom conceptExecutive directorTechnology officerFinancial officerMedia contact